| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1008667383 |
| P356 | DOI | 10.1007/S13317-010-0004-6 |
| P932 | PMC publication ID | 4389060 |
| P698 | PubMed publication ID | 26000103 |
| P5875 | ResearchGate publication ID | 225752569 |
| P50 | author | Ricard Cervera i Segura | Q53547424 |
| Gerard Espinosa | Q60326205 | ||
| P2860 | cites work | Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines | Q22255576 |
| Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant | Q24247000 | ||
| A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS) | Q28174751 | ||
| Antiaggregant and anticoagulant therapy in systemic lupus erythematosus and Hughes' syndrome | Q28182136 | ||
| High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin | Q28185196 | ||
| A study of 75 pregnancies in patients with antiphospholipid syndrome | Q28188872 | ||
| Risk factors associated with fetal losses in treated antiphospholipid syndrome pregnancies: a multivariate analysis | Q28190493 | ||
| A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome | Q28193536 | ||
| Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment | Q28193717 | ||
| Management of antiphospholipid antibody syndrome: a systematic review | Q28195454 | ||
| Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals | Q28210153 | ||
| Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals | Q28217805 | ||
| Real world experience with antiphospholipid antibody tests: how stable are results over time? | Q28218139 | ||
| Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration | Q28282969 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| Clinical study and follow-up of 100 patients with the antiphospholipid syndrome | Q33331100 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. | Q33342481 | ||
| Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study | Q33366716 | ||
| Antiphospholipid Thrombosis: Clinical Course after the First Thrombotic Event in 70 Patients | Q33369688 | ||
| The "primary" antiphospholipid syndrome: major clinical and serological features. | Q33416915 | ||
| A study of sixty pregnancies in patients with the antiphospholipid syndrome. | Q33496452 | ||
| Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Organizing Group of the Antiphospholipid Antibody Treatment Trial | Q33499382 | ||
| A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis | Q33500954 | ||
| Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients | Q33502956 | ||
| Antiphospholipid antibodies and reproduction: the antiphospholipid antibody syndrome. | Q33547975 | ||
| Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment | Q33565796 | ||
| The antiphospholipid syndrome: immunologic and clinical aspects. Clinical spectrum and treatment | Q33899919 | ||
| Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis | Q33964007 | ||
| Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients | Q34435380 | ||
| Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study | Q34619943 | ||
| Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q34788539 | ||
| Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature | Q34977289 | ||
| Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome | Q35158386 | ||
| How to treat women with antiphospholipid antibodies in pregnancy? | Q35549772 | ||
| Cost-effectiveness of testing for hypercoagulability and effects on treatment strategies in patients with deep vein thrombosis | Q35792605 | ||
| Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies) | Q36242479 | ||
| Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review | Q36445071 | ||
| A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies | Q37020336 | ||
| Lessons from the "Euro-Phospholipid" project | Q37055413 | ||
| Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis | Q38553245 | ||
| Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus--a meta-analysis | Q41537096 | ||
| Antiphospholipid antibodies in unselected patients with repeated abortion | Q42125170 | ||
| Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. | Q43417859 | ||
| Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients | Q43519903 | ||
| Detection of antiphospholipid antibodies by immunostaining on thin layer chromatography plates. | Q43999720 | ||
| A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome | Q44588720 | ||
| The G1691 --> A mutation of factor V, but not the G20210 --> A mutation of factor II or the C677 --> T mutation of methylenetetrahydrofolate reductase genes, is associated with venous thrombosis in patients with lupus anticoagulants | Q45867213 | ||
| Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? Yes (in some cases). | Q46508618 | ||
| Heparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antibodies. | Q46728540 | ||
| The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. | Q51766317 | ||
| Bleeding and re-thrombosis in primary antiphospholipid syndrome on oral anticoagulation: an 8-year longitudinal comparison with mitral valve replacement and inherited thrombophilia. | Q52858010 | ||
| Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. | Q53354829 | ||
| Antiphospholipid antibodies and venous thromboembolism | Q54157484 | ||
| ACOG Practice Bulletin #68: Antiphospholipid syndrome | Q56753299 | ||
| Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors in a series of 250 patients | Q56907610 | ||
| Prevention of anticardiolipin antibody-related pregnancy losses with prednisone and aspirin | Q67566965 | ||
| The catastrophic antiphospholipid syndrome | Q68136491 | ||
| Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry | Q71112355 | ||
| Antiphospholipid antibodies, recurrent thromboembolism, and intensity of warfarin anticoagulation | Q71307921 | ||
| Low-dose aspirin for prevention of pregnancy losses in women with primary antiphospholipid syndrome | Q72347443 | ||
| The management of thrombosis in the antiphospholipid-antibody syndrome | Q72619159 | ||
| Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients | Q72671950 | ||
| Anticardiolipin antibodies and recurrent thromboembolism | Q73069585 | ||
| Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial | Q73086844 | ||
| Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone | Q73143663 | ||
| Obstetric outcome in antiphospholipid syndrome | Q73585749 | ||
| Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients | Q74284472 | ||
| Factor V Leiden, prothrombin gene mutation, and thrombosis risk in patients with antiphospholipid antibodies | Q74614839 | ||
| Thromboembolic events after fetal loss in patients with antiphospholipid syndrome: comment on the article by Erkan et al | Q77941137 | ||
| Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus | Q78609890 | ||
| Warfarin-related outcomes in patients with antiphospholipid antibody syndrome managed in an anticoagulation clinic | Q80072386 | ||
| Lupus and thrombosis | Q80231497 | ||
| Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus | Q81352128 | ||
| A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis | Q81831105 | ||
| Genetic variation at the estrogen receptor alpha locus in relation to venous thromboembolism risk among postmenopausal women | Q81888071 | ||
| Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study | Q82045296 | ||
| Family history for venous thromboembolism and the risk for recurrence | Q82345821 | ||
| [Suspension of anticoagulation in patients with primary antiphospholipid syndrome in which a negative antibody antiphospholipid] | Q84471657 | ||
| P433 | issue | 1 | |
| P921 | main subject | antiphospholipid syndrome | Q582207 |
| P304 | page(s) | 15-22 | |
| P577 | publication date | 2010-05-01 | |
| P1433 | published in | Autoimmunity highlights | Q26853848 |
| P1476 | title | Management of the antiphospholipid syndrome | |
| P478 | volume | 1 |
Search more.